Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Tóm tắt
Từ khóa
Tài liệu tham khảo
Moghimi, 2001, Long-circulating and target specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283
Vinagradov, 2002, Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells, Adv. Drug Del. Rev., 54, 223
Song, 1998, Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model, J. Control. Release, 54, 201, 10.1016/S0168-3659(98)00016-9
Thomasin, 1998, Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations, J. Pharm. Sci., 87, 259, 10.1021/js970047r
Vert, 1998, Something new in the field of PLA/GA bioresorbable polymers?, J. Control. Release, 53, 85, 10.1016/S0168-3659(97)00240-X
Jain, 1998, Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches, Drug Dev. Ind. Pharm., 24, 703, 10.3109/03639049809082719
Brem, 2001, Biodegradable polymer implants to treat brain tumors, J. Control. Release, 74, 63, 10.1016/S0168-3659(01)00311-X
Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5, 10.1016/S0169-409X(97)00048-3
Vajdy, 2001, Microparticles for intranasal immunization, Adv. Drug Deliv. Rev., 51, 127, 10.1016/S0169-409X(01)00167-3
Labhasetwar, 1997, Nanoparticles for drug delivery, Pharm. News, 4, 28
Guzman, 1996, Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty, Circulation, 94, 1441, 10.1161/01.CIR.94.6.1441
Labhasetwar, 1990, Nanoparticles—a colloidal drug delivery system for primaquine and metronidazole, J. Control. Release, 12, 113, 10.1016/0168-3659(90)90087-A
Labhasetwar, 1998, Arterial uptake of biodegradable nanoparticles: effect of surface modifications, J. Pharm. Sci., 87, 1229, 10.1021/js980021f
Labhasetwar, 1999, Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model, Colloids Surfaces B: Biointerfaces, 16, 281, 10.1016/S0927-7765(99)00079-X
Desai, 1999, Immune response with biodegradable nanospheres and alum: Studies in rabbits using staphylococcal entertoxin B-toxoid, J. Microencapsul., 17, 215
Desai, 1997, The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent, Pharm. Res., 14, 1568, 10.1023/A:1012126301290
Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: effect of particle size, Pharm. Res., 13, 1838, 10.1023/A:1016085108889
Kroll, 1998, Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood–brain and/or blood–tumor barriers, Neurosurgery, 43, 879, 10.1097/00006123-199810000-00090
Zauner, 2001, In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density, J. Control. Release, 71, 39, 10.1016/S0168-3659(00)00358-8
Sahoo, 2002, Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, J. Control. Release, 82, 105, 10.1016/S0168-3659(02)00127-X
Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0
Langer, 1997, Tissue engineering: a new field and its challenges, Pharm. Res., 14, 840, 10.1023/A:1012131329148
Hanafusa, 1995, Biodegradable plate fixation of rabbit femoral shaft osteotomies. A comparative study, Clin. Orthop., 315, 262
Matsusue, 1995, Tissue reaction of bioabsorbable ultra high strength poly (l-lactide) rod. A long-term study in rabbits, Clin. Orthop., 317, 246
Mooney, 1997, Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges, J. Biomed. Mater. Res., 37, 413, 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C
Eiselt, 1998, Development of technologies aiding large-tissue engineering, Biotechnol. Prog., 14, 134, 10.1021/bp970135h
Lin, 2000, In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters, J. Microencapsul., 17, 577, 10.1080/026520400417630
Cleland, 1997, Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development, Adv. Drug Del. Rev., 28, 71, 10.1016/S0169-409X(97)00051-3
Berkland, 2002, Precise control of PLG microsphere size provides enhanced control of drug release rate, J. Control. Release, 82, 137, 10.1016/S0168-3659(02)00136-0
Tachibana, 1998, Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: Qualitative and quantitative evaluation of intracellular trafficking, Biochem. Biophys. Res. Comm., 251, 538, 10.1006/bbrc.1998.9460
Wattiaux, 2000, Endosomes, lysosomes: their implications in gene transfer, Adv. Drug Del. Rev., 41, 201, 10.1016/S0169-409X(99)00066-6
Sibley, 2000, Cell invasion by un-palatable parasites, Traffic, 1, 100, 10.1034/j.1600-0854.2000.010202.x
Lappalainen, 1994, Comparison of cell proliferation and toxicity assays using two cationic liposomes, Pharm. Res., 11, 1127, 10.1023/A:1018932714745
de Verdiere, 1997, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action, Br. J. Cancer, 76, 198, 10.1038/bjc.1997.362
Bart, 2000, The blood–brain barrier and oncology: new insights into function and modulation, Cancer Treat. Rev., 26, 449, 10.1053/ctrv.2000.0194
Panyam, 2002, Rapid endo-lysosomal escape of poly (d,l-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery, FASEB J., 16, 1217, 10.1096/fj.02-0088com
Panyam, 2003, Dynamics of endocytosis and exocytosis of poly (d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells, Pharm. Res., 20, 110, 10.1023/A:1022219003551
Davda, 2002, Characterization of nanoparticle uptake by endothelial cells, Int. J. Pharm., 233, 51, 10.1016/S0378-5173(01)00923-1
Foster, 2001, Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium, J. Pharm. Pharmacol., 53, 57, 10.1211/0022357011775190
Suh, 1998, Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres, J. Biomed. Mater. Res., 42, 331, 10.1002/(SICI)1097-4636(199811)42:2<331::AID-JBM19>3.0.CO;2-L
Makino, 1986, Transfer of protons form bulk solution to the surface of poly(l-lactide) microcapsules, J. Microencapsul., 3, 195, 10.3109/02652048609031573
Tomoda, 1989, Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages, J. Biol. Chem., 264, 15445, 10.1016/S0021-9258(19)84849-4
Fishbein, 2001, Formulation and delivery mode affect disposition and activity of tryphostin-loaded nanoparticles in the rat carotid model, Arterioscler. Thromb. Vasc. Biol., 21, 1434, 10.1161/hq0901.095567
Hedley, 1998, Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses, Nat. Med., 4, 365, 10.1038/nm0398-365
Labhasetwar, 1998, A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle, J. Pharm. Sci., 87, 1347, 10.1021/js980077+
Cohen, 2000, Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles, Gene Ther., 7, 1896, 10.1038/sj.gt.3301318
Prabha, 2002, Size-dependency of nanoparticle-mediated gene transfection: Studies with fractionated nanoparticles, Int. J. Pharm., 244, 105, 10.1016/S0378-5173(02)00315-0
Clark, 1999, Cationic lipid-mediated gene transfer: current concepts, Curr. Opin. Mol. Ther., 1, 158
Labhasetwar, 1997, Nanoparticle drug delivery for restenosis, Adv. Drug Del. Rev., 24, 63, 10.1016/S0169-409X(96)00483-8
Maheshwari, 2002, Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity, Gene Ther., 9, 1075, 10.1038/sj.gt.3301766
Richardson, 2001, Polymeric system for dual growth factor delivery, Nat. Biotechnol., 19, 1029, 10.1038/nbt1101-1029
Lee, 1998, Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines, Circ. Res., 82, 845, 10.1161/01.RES.82.8.845
Bonadio, 1999, Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration, Nat. Med., 5, 753, 10.1038/10473
Ohno, 1994, Gene therapy for vascular smooth muscle cell proliferation after arterial injury, Science, 265, 781, 10.1126/science.8047883
J. Davda, Nanospheres for the sustained delivery of vascular endothelial growth factor in angiogenesis therapy, M.S. Thesis, Department of Pharmaceutical Sciences. 2000, University of Nebraska Medical Center: Omaha.
van de Weert, 2000, The effect of a water/organic solvent interface on the structural stability of lysozyme, J. Control. Release, 68, 351, 10.1016/S0168-3659(00)00277-7
Lu, 2000, Controlled release of transforming growth factor beta1 from biodegradable polymer microparticles, J. Biomed. Mater. Res., 50, 440, 10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G
Zhu, 2000, Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide), Nat. Biotechnol., 18, 52, 10.1038/71916
Kim, 1999, Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism, Biotechnol. Bioeng., 65, 659, 10.1002/(SICI)1097-0290(19991220)65:6<659::AID-BIT6>3.0.CO;2-9
Chang, 1996, Stabilization of tetanus toxoid in poly(d,l-lactico-co-glycolic acid) microspheres for the controlled release of antigen, J. Pharm. Sci., 85, 129, 10.1021/js950365v
Raghuvanshi, 2001, Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid, J. Microencapsul., 18, 723, 10.1080/02652040110055261
Kreuter, 1976, In vitro studies of poly (methylmethacrylate) adjuvants, J. Pharm. Sci., 65, 1624, 10.1002/jps.2600651115
Jung, 2001, Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice, Pharm. Res., 18, 352, 10.1023/A:1011063232257
Murphy, 2000, Drug delivery to mitochondria: the key to mitochondrial medicine, Adv. Drug Deliv. Rev., 41, 235, 10.1016/S0169-409X(99)00069-1
Lamprecht, 2001, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J. Pharmacol. Exp. Ther., 299, 775
Scherer, 2002, Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo, Gene Ther., 9, 102, 10.1038/sj.gt.3301624
Monsky, 1999, Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor, Cancer Res., 59, 4129
Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzyme Regul., 41, 189, 10.1016/S0065-2571(00)00013-3
Lee, 2000, VEGF gene delivery to myocardium: deleterious effects of unregulated expression, Circulation, 102, 898, 10.1161/01.CIR.102.8.898
Modica-Napolitano, 2001, Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells, Adv. Drug Deliv. Rev., 49, 63, 10.1016/S0169-409X(01)00125-9
Merodio, 2000, Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis, J. Drug Target., 8, 289, 10.3109/10611860008997907
Popma, 1999, Clinical trials in interventional cardiology, Curr. Opin. Cardiol., 14, 412, 10.1097/00001573-199909000-00009
Popma, 1993, Vascular complications after balloon and new device angioplasty, Circulation, 88, 1569, 10.1161/01.CIR.88.4.1569
Bult, 2000, Restenosis: a challenge for pharmacology, Trends Pharmacol. Sci., 21, 274, 10.1016/S0165-6147(00)01505-4
Orford, 2000, The comparative pathobiology of atherosclerosis and restenosis, Am. J. Cardiol., 86, 6h, 10.1016/S0002-9149(00)01094-8
Penn, 2001, Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling, Circ. Res., 89, 1, 10.1161/hh1301.093825
Koster, 1995, Enhanced migratory activity of vascular smooth muscle cells with high expression of platelet-derived growth factor A and B, Angiology, 46, 99, 10.1177/000331979504600202
Wilcox, 1991, Thrombin and other potential mechanisms underlying restenosis, Circulation, 84, 432, 10.1161/01.CIR.84.1.432
Wilcox, 1993, Molecular biology: insight into the causes and prevention of restenosis after arterial intervention, Am. J. Cardiol., 72, 88e, 10.1016/0002-9149(93)91043-H
Christen, 2001, Mechanisms of neointima formation and remodeling in the porcine coronary artery, Circulation, 103, 882, 10.1161/01.CIR.103.6.882
Haudenschild, 1993, Pathobiology of restenosis after angioplasty, Am. J. Med., 94, 40s
Lovqvist, 1993, Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives, J. Intern. Med., 233, 215, 10.1111/j.1365-2796.1993.tb00979.x
Hamon, 1998, Pharmacological approaches to the prevention of restenosis after coronary angioplasty, Drugs Aging, 13, 291, 10.2165/00002512-199813040-00005
O’Brien, 1993, Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy, Circ. Res., 73, 223, 10.1161/01.RES.73.2.223
Brieger, 1997, Local drug delivery systems and prevention of restenosis, Cardiovasc. Res., 35, 405, 10.1016/S0008-6363(97)00155-7
Edelman, 1990, Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury, Proc. Natl. Acad. Sci. U S A, 87, 3773, 10.1073/pnas.87.10.3773
Simons, 1992, Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo, Nature, 359, 67, 10.1038/359067a0
Villa, 1995, Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury, Circ. Res., 76, 505, 10.1161/01.RES.76.4.505
Alt, 1998, Antithrombotic stent coatings: hirudin/iloprost combination, Semin Interv. Cardiol., 3, 177
Grewe, 2000, Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen, J. Am. Coll. Cardiol., 35, 157, 10.1016/S0735-1097(99)00486-6
Cutlip, 2001, Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials, Circulation, 103, 1967, 10.1161/01.CIR.103.15.1967
Dolmatch, 1998, Tissue response to covered Wallstents, J. Vasc. Interv. Radiol., 9, 471, 10.1016/S1051-0443(98)70302-1
Blindt, 1999, Development of a new biodegradable intravascular polymer stent with simultaneous incorporation of bioactive substances, Int. J. Artif. Organs., 22, 843, 10.1177/039139889902201211
Herrmann, 1999, Antithrombogenic coating of stents using a biodegradable drug delivery technology, Thromb. Haemost., 82, 51, 10.1055/s-0037-1614629
Vrolix, 2000, Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial), MENTOR Trial Investigators, Am. J. Cardiol., 86, 385, 10.1016/S0002-9149(00)00951-6
Alt, 2000, Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost, Circulation, 101, 1453, 10.1161/01.CIR.101.12.1453
Ahn, 1999, Preventive effects of the heparin-coated stent on restenosis in the porcine model, Catheter Cardiovasc. Interv., 48, 324, 10.1002/(SICI)1522-726X(199911)48:3<324::AID-CCD20>3.0.CO;2-K
Herdeg, 2000, Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo, J. Am. Coll. Cardiol., 35, 1969, 10.1016/S0735-1097(00)00614-8
Heldman, 2001, Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis, Circulation, 103, 2289, 10.1161/01.CIR.103.18.2289
Sousa, 2001, Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up, Circulation, 104, 2007, 10.1161/hc4201.098056
Honda, 2001, Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system, Circulation, 104, 380, 10.1161/hc2901.094149
Gruberg, 2001, Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries, Expert Opin. Investig. Drugs., 10, 891, 10.1517/13543784.10.5.891
Weissman, 2001, Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population, Am. J. Cardiol., 88, 248, 10.1016/S0002-9149(01)01635-6
Kim, 2001, Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis, J. Am. Coll. Cardiol., 37, 1026, 10.1016/S0735-1097(01)01112-3
Ajani, 2001, Clinical trials of vascular brachytherapy for in-stent restenosis: update, Cardiovasc. Radiat. Med., 2, 107, 10.1016/S1522-1865(00)00081-0
Kollum, 2001, Delayed re-endothelialization and T-cell infiltration following intracoronary radiation therapy in the porcine model, Int. J. Radiat. Oncol. Biol. Phys., 50, 495, 10.1016/S0360-3016(01)01497-3
Kastrati, 2001, Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial, Circulation, 103, 2816, 10.1161/01.CIR.103.23.2816
Kornowski, 1998, In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia, J. Am. Coll. Cardiol., 31, 224, 10.1016/S0735-1097(97)00450-6
Farb, 2001, Pathological analysis of local delivery of paclitaxel via a polymer-coated stent, Circulation, 104, 473, 10.1161/hc3001.092037
Hofma, 1998, Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model, Eur. Heart. J., 19, 601, 10.1053/euhj.1997.0753
Hwang, 2001, Physiological transport forces govern drug distribution for stent-based delivery, Circulation, 104, 600, 10.1161/hc3101.092214
Matsuda, 2001, Terminally alkylated heparin. 1. Antithrombogenic surface modifier, Biomacromolecules, 2, 1169, 10.1021/bm0100965
Gohda, 2001, Terminally alkylated heparin. 2. Potent antiproliferative agent for vascular smooth muscle cells, Biomacromolecules, 2, 1178, 10.1021/bm010097x
Choussat, 2001, Long-term (> or =8 years) outcome after Palmaz-Schatz stent implantation, Am. J. Cardiol., 88, 10, 10.1016/S0002-9149(01)01577-6
Raman, 1998, Coated stents: local pharmacology, Semin. Interv. Cardiol., 3, 133
Ye, 1998, Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall, Ann. Biomed. Eng., 26, 398, 10.1114/1.62
Mitchel, 1995, Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies, Circulation, 91, 785, 10.1161/01.CIR.91.3.785
Baumbach, 1997, Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery, Cathet. Cardiovasc. Diagn., 41, 303, 10.1002/(SICI)1097-0304(199707)41:3<303::AID-CCD11>3.0.CO;2-O
Kiesz, 2001, Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish–American Local Lovenox NIR Assessment study (The POLONIA study), Circulation, 103, 26, 10.1161/01.CIR.103.1.26
Lehmann, 2000, Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans, J. Am. Coll. Cardiol., 35, 583, 10.1016/S0735-1097(99)00603-8
Hong, 1997, Feasibility and efficacy of locally delivered enoxaparin via the Channeled Balloon catheter on smooth muscle cell proliferation following balloon injury in rabbits, Cathet. Cardiovasc. Diagn., 41, 241, 10.1002/(SICI)1097-0304(199707)41:3<241::AID-CCD3>3.0.CO;2-6
Axel, 1997, Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery, Circulation, 96, 636, 10.1161/01.CIR.96.2.636
Creel, 2000, Arterial paclitaxel distribution and deposition, Circ. Res., 86, 879, 10.1161/01.RES.86.8.879
Herdeg, 1998, Antiproliferative stent coatings: Taxol and related compounds, Semin. Interv. Cardiol., 3, 197
Riessen, 1993, Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon, Hum. Gene Ther., 4, 749, 10.1089/hum.1993.4.6-749
Mitchel, 1994, Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons, Circulation, 90, 1979, 10.1161/01.CIR.90.4.1979
Fram, 1994, Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion, J. Am. Coll. Cardiol., 23, 1570, 10.1016/0735-1097(94)90658-0
Azrin, 1997, Local delivery of c-myb antisense oligonucleotides during balloon angioplasty, Cathet. Cardiovasc. Diagn., 41, 232, 10.1002/(SICI)1097-0304(199707)41:3<232::AID-CCD2>3.0.CO;2-7
Panyam, 2002, Efficiency of Dispatch® and Infiltrator® cardiac infusion catheters in arterial localization of nanoparticles in a porcine coronary model of restenosis, J. Drug Target, 10, S15, 10.1080/1061186021000038391
Dev, 1997, Sustained local drug delivery to the arterial wall via biodegradable microspheres, Cathet. Cardiovasc. Diagn., 41, 324, 10.1002/(SICI)1097-0304(199707)41:3<324::AID-CCD14>3.0.CO;2-N
Gradus Pizlo, 1995, Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery, J. Am. Coll. Cardiol., 26, 1549, 10.1016/0735-1097(95)00345-2
March, 1994, Biodegradable microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle cells, Circulation, 89, 1929, 10.1161/01.CIR.89.5.1929